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http://www.biomedcentral.com/1471-244X/14/138RESEARCH ARTICLE Open AccessThe relationship between neurocognition and
symptomatology in people with schizophrenia:
social cognition as the mediator
Bess YH Lam1, Adrian Raine3* and Tatia MC Lee1,2,4,5*Abstract
Background: The relationship between neurocognition and symptomatology in people with schizophrenia has
been established. The present study examined whether social cognition could mediate this relationship.
Methods: There were 119 participants (58 people with paranoid schizophrenia and 61 healthy controls)
participated in this study. Neurocognition was assessed by Raven’s Progressive Matrices Test, the Judgment of Line
Orientation Test, and the Tower of London Test. Psychiatric symptoms in people with schizophrenia were assessed
by the Positive and Negative Syndrome Scale. Social cognition was measured by the Faux Pas Test, the “Reading
the Mind in the Eyes” Test, and the Interpersonal Reactivity Index.
Results: Results were consistent with previous findings that neurocognition and social cognition were impaired in
the clinical participants. A novel observation is that social cognition significantly mediated the relationship between
neurocognition and symptomatology.
Conclusions: These findings suggest that neurocognitive deficits predispose people with schizophrenia to worse
psychiatric symptoms through the impairment of social cognition. Findings of the present study provide important
insight into a functional model of schizophrenia that could guide the development of cost-effective interventions
for people with schizophrenia.
Keywords: Cognition, Faux pas, Eyes test, Theory of mind, Schizophrenia, EmotionBackground
Neurocognitive impairment is a well-studied feature of
schizophrenia [1-4], and its association with functional
impairment has been well validated [4-8]. For instance,
people with schizophrenia scored lower on executive func-
tioning, which is one aspect of neurocognitive functioning
when compared to the healthy controls. Also, this impair-
ment was related to negative symptoms in these people
[4]. However, prior studies often collapsed and treated neu-
rocognition as one single domain [9]. Since neurocognition
is a broad construct encompassing visual and verbal learn-
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unless otherwise stated.further studies on the relationship between this construct
and functional impairment or symptomatology are needed.
The association of neurocognition with negative symptoms
has been widely studied [4,10,11], while positive and gen-
eral symptoms have received much less attention in prior
studies. The meta-analysis in 73 studies revealed that nega-
tive symptoms were associated with worse neurocognition
and functional outcomes in schizophrenia [11]. Specifically,
negative symptoms were related to deficits in problem
solving, reasoning, executive functioning [4,12,13], and IQ
[14]. However, the findings regarding the association be-
tween neurocognition and positive symptoms were scarce
and inconsistent [11,15,16]. According to Ventura and col-
leagues [11], positive symptoms were not significantly re-
lated to neurocognition and functional outcomes [17],
while Rabinowitz and colleagues found the opposite [18].
Taken together, these findings suggest that neurocognition
is more closely associated with negative than with positive. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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neglected in prior studies. Therefore, further studies are
warranted for the investigation of the relation of neuro-
cognition to symptomatology, including negative, positive,
and general symptoms in schizophrenia. Prior longitudinal
studies found that neurocognitive deficits predicted the
onset of psychosis [19,20] as well as negative symptoms at
the 1-year follow up in first-episode psychosis [14]. Specif-
ically, the review [19] has revealed that neurocognitive def-
icits exist prior to the onset of psychosis. These findings
were consistent with the argument by Comblatt and Keilp
[21] that neurocognitive deficits lead to social and emo-
tional impairment, and this is reflected in the negative
symptoms in schizophrenia. Hence, we hypothesized that
neurocognitive deficits predicted the severity of symptoms
instead of the other way around in the present study [11].
Because neurocognition alone could account for only
20–60% of the variance in functional outcomes [7], so-
cial cognition, which is a common correlate of both
constructs [6], has been speculated to be a potential
candidate to explain the neurocognition-functional out-
comes relation [9,22]. Social cognition, which is also
impaired in people with schizophrenia [23,24], covers
a range of constructs: theory of mind (ToM) or self-
representation, emotion perception or empathy, and so-
cial perception [25]. Specifically, regarding ToM, people
with schizophrenia performed worse than healthy con-
trols in the Faux Past Test after controlling for age and
gender [26] as well as in the “Reading the Mind in the
Eyes” Test [27]. In terms of empathy as measured by
Interpersonal Reactivity Index (IRI), these people scored
worse in two subscales (perspective taking and personal
distress), but there was no significant difference in the
other two subscales (fantasy and empathetic concern)
[28]. These suggest that some aspects of empathy might
be retained even in neurocognitively impaired individuals.
A review of 15 prior studies showed that various social-
cognitive domains, including ToM, emotion perception,
empathy, and social perception, were significant mediators
in such a relation [9]. Also, [29-31] found that social cog-
nition assessed by objective measures such as the Facial
Emotion Identification Test [32] and the Half-profile of
Nonverbal Sensitivity [33] played a significant role in the
functional outcomes in schizophrenia as well as in the
clinical high-risk-for-psychosis group [34]. These findings
suggest that neurocognitive impairment may have an ad-
verse impact on social-cognitive functioning, which in turn
predisposes people with schizophrenia to poor functional
outcomes. More importantly, it leads to the speculation
that social cognition may also mediate the relation be-
tween neurocognition and symptomatology in schizophre-
nia [35]. However, this hypothesis was scarcely examined.
Moreover, prior studies regarding social cognition suf-
fered from a common limitation: they often focused ononly one domain of the multi-dimensional social cognition
construct at a time [9]. It was found that only 3 out of 15
studies investigated more than one domain of social cog-
nition [9]. Among these studies, relatively few were done
to explore empathy, which is also considered as one do-
main of social cognition [36], and the findings have been
inconsistent. For instance, empathy assessed by IRI, which
is a self-report scale, was found to be negatively associated
with negative symptoms in schizophrenia in some studies
[37,38]. However, its association with symptomatology
encompassing negative, positive, and disorganized symp-
toms was not significant in other studies using the same
assessment, IRI [39,40]. These inconsistent results might
be due to two factors: (1) Different types of psychotic dis-
orders were examined in these studies. Specifically, people
with schizophrenia [37,38] and people with first-episode
psychosis [39] were examined respectively. (2) Self- ratings
of social cognition might be more biased when compared
to the objective measures [29,31] in schizophrenia. Further
studies are warranted to address these inconsistencies and
speculations.
The present study extended previous studies by examin-
ing a broader concept of social cognition and symptom-
atology and separating neurocognition into various factors.
Prior studies have focused on certain neurocognitive as-
pects such as executive functions, working memory, and
attention and its relation with symptomatology in schizo-
phrenia, while other aspects such as visual and spatial
learning and memory were overlooked [11]. Therefore, the
present study investigated perception, which has been less
investigated in prior literature. Besides that, executive
functioning, which is the core neurocognitive impairment
in schizophrenia and shares substantial variances with
working-memory capacity (r = .97), was also examined
[41]. All in all, the primary goals of the present study were
to examine the neurocognitive (executive functioning and
perception) and social cognitive (theory of mind and em-
pathy) abilities and to examine whether social cognition
played a mediating role in the relation of neurocognition
to negative, positive, and general psychopathological symp-
toms in schizophrenia. It was hypothesized that both of
these abilities were impaired in schizophrenia but not in
healthy controls. Moreover, it was hypothesized that theory
of mind as well as empathy would mediate the association
between neurocognitive abilities (executive functioning or
perception) and symptomatology (negative, positive, and
general symptoms) in schizophrenia.
Methods
Participants
One hundred and nineteen Chinese participants (58
people with the diagnosis of paranoid schizophrenia and
61 healthy controls) with a mean age of 40.62 years (SD =
9.23 years) were recruited. The inclusion criteria for
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munity were the following: (1) no history of mental health
illness, head injury, neurological disorders, or medical dis-
eases that might have affected brain functioning; (2) no
history of substance or alcohol abuse, or of mental defi-
ciency; and (3) normal or corrected-to-normal vision and
hearing. The paranoid schizophrenia group (male = 29, fe-
male = 29) was recruited based on the following criteria:
(1) either inpatients or outpatients of a local psychiatric
hospital; (2) diagnosed with paranoid schizophrenia with
the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (Text Revision) [42]; (3) no history of head
injury, neurological disorders, or medical diseases that
might have affected brain functioning other than paranoid
schizophrenia; (4) on antipsychotic medications; and 5) not
diagnosed with other co-morbid Axis I or II conditions.
Age, education, and sex were matched across the two
groups. The mean age for healthy controls and the people
with schizophrenia were 41.3 years (SD = 9.5 years) and
40.0 years (SD = 9.0 years), respectively. The healthy con-
trols attained a mean of 11.3 years of education (SD =
2.7 years) while the schizophrenia group had a mean of
10.4 years of education (SD = 3.0 years). The schizophrenia
group with the mean duration of illness of 13.4 years
(SD = 8.8 years) and mean onset age of 25.9 years
(7.5 years) included both inpatients (n = 23, 39.7%) and
outpatients (n =35, 60.3%). These two subgroups did not
differ significantly in terms of age, duration of illness, age
of onset, and education, but did differ in the proportion of
sex (inpatients: 16 male and 7 female; outpatients: 13 male
and 22 female). The ethics approval of the current study
was granted by the New Territories West Cluster Clinical
Research and Ethics Committee. Upon the receipt of a
written informed consent from the participants, they were
assessed with the following measures (except that symp-
tomatology was only assessed in the schizophrenia group).
Measures
The Tower of London Test (TOL) [43] was administered
to assess executive functioning, particularly with regard
to planning, processing, and problem-solving skills. In
this task, a set of three beads was first strategically
placed on three rods with descending heights, and par-
ticipants were then asked to rearrange the beads from a
preset starting position using a different set of beads and
rods to match the original set of beads. Participants’ per-
formances were measured in terms of the accuracy of
the solution (TOL accuracy), the efficiency of the solu-
tion (TOL time), and rule breaks during the solution
(TOL score). The accuracy was measured by the rate of
correct moves while the efficiency was indexed by the
total time taken to solve all solutions. This measure was
reported to be sensitive to problem difficulty [44]. The
less time used, the more efficient the participant was.the TOL score was calculated by how compliant the par-
ticipants were with the three basic rules: (1) do not put
more than the number of balls allowed on any peg, (2)
only place the balls on the peg but nowhere else, and (3)
only move one ball at a time.
Judgment of Line Orientation Test (JLOT) [45] con-
tains 30 items that assess visuo-spatial processing. In this
test, the participants were presented with stimuli, each
consisting of 11 lines separated by an angle of 18°. They
were then asked to match a pair of lines with the array
of 11 stimulus lines. Each correct answer was given one
point, and the total score was thereby computed.
Raven’s Progressive Matrices Test (RPM) [46], which is
designed for assessing general intelligence, was adminis-
tered to all participants. RPM has been widely used in
practice and research, and it consists of a series of dia-
grams or designs with a part missing. Participants were
given a number of choices, which were placed below the
diagrams, and were asked to choose the appropriate item
to fill in the missing part.
Faux Pas Test (FP) [47], which consists of 20 stories
including 10 faux pas and 10 control stories, was used to
assess the first and second order of theory of mind
(ToM). During the test, a research assistant read 20 stor-
ies to the participants in random order, and then the
participants were asked to answer three to six questions
(FP Q1–Q6), depending on whether a faux pas was de-
tected (Table 1). In short, FP Q1 measured the ability of
the participants to detect a faux pas (detection); FP Q2
measured their ability to identify the person who com-
mitted the faux pas (identification); FP Q3 measured
their ability to interpret the recipient’s mental state; FP
Q4 measured their ability to understand the speaker’s
intention; and FP Q5 and Q6 measured their ability to
recall specific story content.
The participants needed to answer questions FP Q2 to
Q4 as listed above only if they detected a faux pas (FP Q1)
in the stories (both faux pas and control stories). If no faux
pas was detected, FP Q2 to Q4 were omitted. In either
case, the control questions (FP Q5 and Q6) were adminis-
tered to the participants. One point was given for each
correct answer, and zero points were given otherwise. Four
subscores (FP Q1–Q4) were computed for analysis in the
present study by summing the points awarded in 10 faux
pas stories, and the total score was derived by the summa-
tion of the four subscores (FP Q1–Q4 ). All scores (FP
Q1–Q6) for the 10 control stories as well as the “control
questions” (FP Q5–Q6) for the 10 faux pas stories were
not used for analyses in the present study. In the present
study, the reliabilities for this test were 0.74–0.76 and
0.71–0.83 for healthy controls and people with schizo-
phrenia, respectively.
Reading the Mind in the Eyes Test (Eyes Test) [48]
was administered to examine ToM or the participants’
Table 1 Questions of faux pas test
Participants were asked to answer the following questions for each story read by the research assistant:
Q1. Detect a faux pas: “In the story, did anyone say something that they should not have said or something awkward?”
Q2. Identify who committed the faux pas: “Who said something that they should not have said or something awkward?”a
Q3. Interpret the recipient’s mental state: “Why shouldn’t he/she have said it?”a
Q4. Understand the speaker’s intention: “Why do you think he/she said it?”a
Q5. & Q6. Recall specific story content, for example: “Who won the competition?”b
aThis question was only asked if the answer to Q1 was yes.
bControl questions.
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shown a total of 36 black-and-white eye pictures depicting
various mental states. After each stimulus presentation,
they were asked to choose from four choices the most ap-
propriate mental state description (e.g., “upset”) for each
eye picture. The reliabilities obtained were 0.17 (healthy
controls) and 0.52 (people with schizophrenia). The low
reliability of this test for the former group was expected
due to the ceiling effect found in nonclinical partici-
pants [49].
The Interpersonal Reactivity Index (IRI) [50] was ad-
ministered to measure empathy. This 28-item IRI con-
sists of four subscales assessing both cognitive and
emotional empathy. Only the total score, derived by
summing all four subscores, was used for analysis in the
present study. Its reliabilities in healthy controls (α =
0.73) and people with schizophrenia (α = 0.70) were good
in the present study.
Positive and Negative Syndrome Scale (PANSS) [51]
was administered to the clinical participants to assess
symptom severity in adults with schizophrenia, schizoaf-
fective disorder, or other psychotic illnesses. A total of
30 items consists of three subscales: positive, negative,
and general psychopathology. The original three-factor
PANSS was used for analysis in the present study, and
the reliabilities were 0.56 (positive), 0.77 (negative), and
0.58 (general).
Statistical analysis
Between-group differences (schizophrenia group vs. con-
trol group) in terms of neurocognitive and social-cognitive
measures were tested with multivariate analysis of vari-
ance (MANOVA). Specifically, the dependent variables in-
cluded for MANOVA were neurocognitive (RPM, JLOT,
and TOL) and social-cognitive (FP subscores and IRI)
measures. Also, age, sex, and education were included as
covariates in all MANOVA and mediation analyses. In the
schizophrenia group, mediation of social cognition in the
relation between neurocognition and symptomatology was
examined using SPSS PROCESS macro [52] with the boot-
strapping method outlined by Shrout and Bolger [53].
SPSS PROCESS macro is a computational tool for path
analysis-based moderation and mediation analysis as wellas their combination as a “conditional process model.”
Various measures of effect size for indirect effects are gen-
erated in mediation models, along with bootstrap confi-
dence intervals for effect size inference [52]. Specifically,
the SPSS PROCESS macro commands were used to com-
pute the direct estimate of neurocognitive functioning on
psychiatric symptoms (path (C) listed in Table 2) as well
as the total (path (C) + (C’) listed in Table 2) and specific
indirect effects (path (C’) listed in Table 2) of neurocogni-
tive functioning on psychiatric symptoms through social
cognitive functioning. Age, education, and sex were in-
cluded in the model as covariates. However, duration of
illness and onset of illness were not included as covariates
in the mediation analyses because their correlations with
all major variables including “perception,” “execution
functioning,” “empathy,” “theory of mind,” and “symptom-
atology” (negative, positive, and general symptoms) were
not significant (Table 3). Bootstrapping was used to esti-
mate indirect effects, and 95% bias-corrected confidence
intervals were used for the indirect effects using 1,000
bootstrap samples [53].
Results
Social and neurocognitive abilities across groups
One-way MANOVA results showed that healthy con-
trols had significantly better neurocognitive (Wilk’s λ =
0.55, F5, 110 = 17.87, P < 0.001) and social cognitive (Wilk’s
λ = 0.69, F6, 109 = 8.09, P = 0.000) abilities than the schizo-
phrenia group had after controlling for age, sex, and educa-
tion. In terms of neurocognitive abilities, healthy controls
performed significantly better on the RPM, JLOT, and all
three TOL measures (Ps < 0.05) after controlling for age,
sex, and education. These were consistent with prior find-
ings [2,3]. However, after adding the social cognition abil-
ities (FP Q1–Q4 and Eyes Test scores) as covariates, the
effect was not significant for all three TOL subscores (P >
0.05). For social cognitive abilities, healthy controls per-
formed significantly better on the detection (FP Q1) and
identification (FP Q2) of faux pas as well as on the Eyes
Test (Ps < 0.05) after controlling for age, sex, education,
and neurocognitive abilities (RPM, JLOT, and all three
TOL subscores). These were consistent with the prior find-
ings [26,27]. The group differences were not significant in
Table 2 Statistical tests for the social cognition mediation in neurocognition- symptomatology relation
Neurocognitive
functioning- social
cognitive
functioning
Psychiatric
symptoms
A
Estimate
(P-value)
B
Estimate
(P-value)
C
Estimate
(P-value)
C’
Estimate
(P-value)
Indirect effect
(Lower limit 95%
CI, upper limit
95% CI)
Effect size
of the
indirect
effect
Controlling
for
education,
age and sex
A
Estimate
(P-value)
B
Estimate
(P-value)
C
Estimate
(P-value)
C’
Estimate
(P-value)
Indirect effect
(Lower limit 95%
CI, upper limit
95% CI)
Perception- ToM Negative
symptoms
0.36**
(0.0053)
−0.99*
(0.0227)
−0.97*
(0.0201)
−0.62
(0.1469)
−0.3553
(−0.9668, −0.0480)
0.0603 0.33*
(0.0274)
−0.97*
(0.0302)
−1.03*
(0.0334)
−0.71
(0.1399)
−0.3159
(−1.0705, −0.0077)
Executive
functioning - ToM
0.26*
(0.0200)
−1.03*
(0.0159)
−0.78*
(0.0290)
−0.52
(0.1464)
−0.2667
(−0.6880, −0.0518)
0.0498 0.23*
(0.0405)
−0.99*
(0.0266)
−0.76*
(0.0405)
−0.53
(0.1491)
−0.2279
(−0.6625, −0.0149)
Perception- ToM Positive
symptoms
0.36**
(0.0053)
−0.62*
(0.0520)
−0.14
(0.6448)
0.08
(0.7849)
−0.2199
(−0.6595, −0.0223)
0.0026 0.33*
(0.0274)
−0.64*
(0.0530)
−0.20
(0.5676)
0.01
(0.9804)
−0.2071
(−0.7150, 0.0044)
Executive
functioning - ToM
0.26*
(0.0200)
−0.49
(0.1097)
−0.39
(0.1158)
−0.27
(0.2991)
−0.1261
(−0.3579, −0.0118)
0.0254 0.23*
(0.0405)
−0.54
(0.0947)
−0.42
(0.1129)
−0.29
(0.2743)
−0.1238
(−0.3888, −0.0027)
Perception – ToM General
symptoms
0.36**
(0.0053)
−0.55
(0.1300)
−0.53
(0.1256)
−0.32
(0.3659)
−0.1978
(−0.6631, 0.0324)
0.0275 0.33*
(0.0274)
−0.53
(0.1554)
−0.65
(0.1030)
−0.47
(0.2469)
−0.1735
(−0.7176, 0.0364)
Executive
functioning - ToM
0.26*
(0.0200)
−0.46
(0.1797)
−0.69*
(0.0162)
−0.57*
(0.0545)
−0.1204
(−0.3798, 0.0361)
0.0377 0.23*
(0.0405)
−0.46
(0.2045)
−0.71*
(0.0169)
−0.60*
(0.0477)
−0.1061
(−0.4127, 0.0351)
Note: (A) Regression slope of neurocognitive functioning predicting social cognitive functioning; (B) regression slope of social cognitive functioning predicting psychiatric symptoms, controlling for neurocognitive
functioning; (C) regression slope of neurocognitive functioning predicting psychiatric symptoms; (C’) regression slope of neurocognitive functioning predicting psychiatric symptoms, controlling for social cognitive
functioning. Bootstrapping was used to estimate indirect effects (Shrout & Bolger, 2002).
*P < = 0.05.
**P < =0.01.
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Table 3 Zero-order correlations among major variables and demographics in participants with schizophrenia
1 2 3 4 5 6 7 8 9 10 11
1 Duration of illness 1 - - - - - - - - - -
2 Age of onset −0.43** 1 - - - - - - - - -
3 Age 0.55** 0.43** 1 - - - - - - - -
4 Education −0.05 −0.07 −0.17 1 - - - - - - -
5 Perception 0.14 −0.11 0.01 0.45** 1 - - - - - -
6 Executive functioning 0.09 −0.03 −0.01 0.17 0.31* 1 - - - - -
7 Theory of mind −0.07 −0.01 −0.13 0.27* 0.36** 0.31* 1 - - - -
8 Empathy 0.05 −0.02 0.05 −0.13 −0.07 0.41** 0.02 1 - - -
9 Negative symptoms −0.08 0.04 0.00 −0.17 −0.31* −0.29* −0.38** −0.06 1 - -
10 Positive symptoms 0.00 −0.07 −0.01 0.00 −0.06 −0.21 −0.26* −0.13 0.14 1 -
11 General symptoms −0.22 0.14 0.02 −0.08 −0.20 −0.31* −0.26* 0.10 0.48** 0.58** 1
*P < = 0.05.
**P < = 0.01.
Lam et al. BMC Psychiatry 2014, 14:138 Page 6 of 10
http://www.biomedcentral.com/1471-244X/14/138terms of the ability to interpret a recipient’s mental states
(FP Q3) and understand a speaker’s intention (FP Q4) or
empathy measured by IRI (Ps > 0.05). These were not con-
sistent with previous findings [26,28]. These between-
group results are summarized in Table 4.
Mediation analyses in people with schizophrenia
The present study adopted the well-established factor
structure of neurocognition (perception and executive
functioning) and social cognition (theory of mind (ToM)Table 4 Mean (SD) comparison of major variables after contro
Healthy
controls
(n = 61)
Schizophrenia
(n = 58)
F-statistic/group
difference
P-values
Par
Squ
Neurocognitive measuresa 17.87*** 0.45
Raven’s PM 49.8 (7.3) 34.9 (10.6) 0.000*** 0.41
JLOT 24.1 (4.7) 19.0 (6.4) 0.000*** 0.16
TOL
Total time (ms)b 492.2
(131.3)
563.5 (144.4) 0.003** 0.08
Total score 16.7 (3.7) 14.2 (4.1) 0.002** 0.09
Accuracy 1.91 (0.5) 1.7 (0.6) 0.34* 0.40
Social-cognitive measuresa 8.09*** 0.31
FP Q1 (detection) 7.4 (2.3) 5.8 (2.5) 0.001** 0.10
FP Q2 (identification) 7.4 (2.4) 5.6 (2.5) 0.000*** 0.12
FP Q3
(others’ mental states)
2.8 (2.5) 3.3 (2.8) 0.34c 0.01
FP Q4 (intention) 4.1 (2.7) 3.2 (2.4) 0.10c 0.02
ET 22.7 (3.1) 19.1 (4.1) 0.000*** 0.18
Empathy 62.0 (11.4) 62.2 (12.2) 0.96c 0.00
aRaven’s PM = Raven’s Progressive Matrices Test, JLOT = Judgment of Line Orientatio
bms =millisecond; cn.s. = not significant.
*P < = 0.05; **P < = 0.01; ***P < = 0.001.and empathy) for mediation analyses. For the mediation
analyses, the composite scores of neurocognition and social
cognition while the separate subscores of symptomatology
(negative, positive, and general) were used. Specifically, the
composite score of perception was computed by taking the
sum of the standardized scores of RPM and JLOT, while
the execution functioning composite score was calculated
by summing up three standardized subscores of TOL with
the score reversion of TOL total time. The composite
score of ToM was computed by taking the sum of thelling for sex as covariates
tial Eta
ared
Controlling for age,
sex, education and
neurocognitive/
social cognitive measures
F-statistic/group
difference P-values
Partial Eta
Squared
9.33*** 0.31
0.000*** 0.29
0.04* 0.04
0.08c 0.03
0.08c 0.03
0.33c 0.01
2.69* 0.13
0.03* 0.04
0.02* 0.05
0.75c 0.001
0.79c 0.001
0.04* 0.04
1.00c 0.000
n Test, TOL = Tower of London Test, FP = Faux Pas, and ET = Eyes Test;
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indexed by the total IRI score. Since the correlations of
empathy with neurocognitive and social cognitive compos-
ite scores were not significant except for the association
with the executive functioning composite score (r = .41,
P < 0.01) (Table 3), the mediation analyses were only per-
formed for the ToM composite score but not with empathy
as a mediator. A confidence interval that does not contain
zero indicates statistically significant mediation (P < 0.05)
[53]. The mediation statistics are summarized in Table 2.
Negative symptoms as DV
ToM fully mediated the relation between neurocogni-
tive abilities (perception or executive functioning) and
negative symptoms after controlling for all covariates (95%
CI = −1.0705 to −0.0077 for perception; 95% CI = −0.6625
to −0.0149 for executive functioning) (Table 2). Perception
(β = −1.03, P = 0.03) and executive functioning (β = −0.76,
P = 0.04) as well as ToM (βs = −0.97, −0.99, Ps = 0.03)
were negatively associated with negative symptoms,
which was expected [2-4,26,54]. The association of per-
ception (β = −0.71, P = 0.14) and executive functioning
(β = -0.53, P = 0.15) with negative symptoms was abol-
ished after controlling for ToM and all covariates.
Positive symptoms
ToM fully mediated the relation between executive
functioning and positive symptoms after controlling for all
covariates (95% CI = −0.3888 to −0.0027). Executive func-
tioning (β = −0.42, P = 0.11) and ToM (β = −0.54, P = 0.09)
were negatively associated with positive symptoms, which
was also expected [26,54]. However, such mediation was
not significant for the perception–positive symptoms rela-
tion (95% CI = −0.7150 to 0.0044) (Table 2).
General symptoms as DV
ToM did not significantly mediate the relation between
neurocognitive abilities (perception or executive func-
tioning) and general symptoms (95% CI = −0.7176 to
0.0364 for perception; 95% CI = −0.4127 to 0.0351 for
executive functioning) with or without controlling for all
covariates (Table 2).
Discussion
To the best of our knowledge, this is the first study
attempting to explore the role of social cognition in the re-
lation between neurocognition and a broader spectrum
of symptomatology in people with schizophrenia. Overall
findings were consistent with prior studies’ findings that
neurocognition and social cognition are impaired in
schizophrenia [1,24]. More importantly, it was found that
theory of mind (ToM) was a significant mediator explain-
ing the relation of neurocognition to negative and positive
symptoms [9]. However, empathy was not a significantmediator of such a relation, which is contrary to our hy-
pothesis and to prior findings [22,37,38]. Overall findings
suggest that social cognitive ability is one of the underlying
factors of the neurocognition-symptomatology relation in
schizophrenia, which has clinical implications for more
cost-effective interventions for schizophrenia.
As expected, healthy controls had significantly better
performance on perception, executive functioning [1], and
all ToM measures [24], except for reasoning and inference
of others’ mental states. These suggest that neurocogni-
tion, specifically the ability to perceive and understand the
surrounding environment, along with visuo-spatial pro-
cessing, planning, and problem-solving skills are impaired
in people with schizophrenia. Furthermore, these findings
suggest that these people also have social cognitive deficits
in which they lack the ability to detect a faux pas and
identify the person who has committed the faux pas in a
social interaction.
However, empathy as measured by IRI was not im-
paired in these people, which is contrary to our hypoth-
esis. One possible reason for the insignificant differences
across groups might be that IRI [50] is not sensitive
enough to detect such social cognitive deficits in schizo-
phrenia in the Chinese context. Another reason might
be that IRI is a self-report empathy scale, and schizo-
phrenic subjects might be biased about their self-ratings
on their social cognitive abilities. Thus, it might be more
sensitive to detect the difference using objective empathy
measures. Third, the inconsistent results might also be
due to the fact that possible aspects such as age and
education level of the participants were not accounted
for in the group comparison analyses in prior findings
[28] while the medication conditions were not accounted
for in the present study. These speculations should be
investigated in future studies.
In attempting to explain the relation between neurocog-
nitive abilities and negative or positive symptoms in
schizophrenia, ToM was found to be a full mediator. Spe-
cifically, the findings of the present study suggest that im-
pairments in perception or executive functioning worsen
the interpretation and understanding of others’ mental
states or intentions. This in turn leads to more negative
symptoms in schizophrenia [6,15]. In other words, the def-
icits in the organization, identification, and interpretation
of sensory information in order to represent and under-
stand the environment as well as problem-solving skills
affect the ability to detect social cues and faux pas while
interacting with others in schizophrenia. This in turn af-
fects their social functioning including their ability to ex-
perience pleasure in their social interactions. In addition,
it is suggested that impaired executive functioning leads to
more positive symptoms through increased ToM deficits
in schizophrenia. This suggests that the lack of ability to
control and regulate cognitive processes such as working
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people with schizophrenia worsens their capacity to de-
tect social cues and faux pas while interacting with
others. This further leads to more abnormal outcomes
such as hallucinations, delusions, and bizarre behaviors
in these people.
Contrary to our expectation [35], ToM could not explain
the relation between perception and positive symptoms
because perception was not related to positive symptoms
(r = −0.06) in the present study [11]. This inconsistent
finding might be because the strength of the relation be-
tween positive symptoms and different neurocognitive do-
mains varies or because different neurocognitive measures
were used in prior studies [11,15,16]. On the other hand,
theory of mind (ToM) did not mediate the relation
between neurocognition and general psychopathological
symptoms, which was not expected. This finding suggests
that the ability to understand and identify others’ mental
states and intentions does not explain the relation of neu-
rocognition to general symptoms in schizophrenia. One of
the reasons for this finding is that the general psycho-
pathological symptoms encompass a variety of symptoms,
and it is possible that some of these symptoms are more
closely related to certain domains of neurocognition and
social cognition but that others are not. For instance, poor
insight might be more associated with ToM than with em-
pathy. Future studies should further examine the relation
of specific general symptoms with neurocognition and
social cognition. Furthermore, another social cognitive
domain, empathy, was not related to any psychiatric symp-
toms, which is also inconsistent with prior findings.
This might be because this domain was evaluated by
different measures in different psychotic disorders pre-
viously [22,37-39].
Limitations
The current study suffers from five major limitations.
First, the mediation analyses performed with neurocogni-
tion, social cognition, and symptomatology were based on
cross-sectional data. Therefore, we could not conclude the
causality of the mediated relationship found in the present
study. However, the current study is an essential step to-
ward confirming the association between neurocognition,
social cognition, and symptomatology in schizophrenia
before a longitudinal study in perception is undertaken.
Second, due to the time constraints for assessing each par-
ticipant, empathy and executive functioning were each
only assessed by one scale, the Interpersonal Reactivity
Index [50] and the Tower of London [43], respectively.
This might not fully capture the whole dimension of em-
pathy and executive functioning. Third, the present study
only included theory of mind and empathy as the concept
of social cognition, while only perception and executive
functioning were included to represent neurocognition(also because of the time constraint factor). Future studies
should include more measurement tools so to fully repre-
sent these concepts. For instance, social knowledge and at-
tribution styles, which are social-cognitive domains and
often neglected in prior studies, warrant further investiga-
tion [9]. Also, working-memory and attention processes
should also be assessed in the future. Fourth, the self-
report measure was used to assess empathy in the present
study while the other social cognition domain, theory of
mind, was tested by objective measures. Since there might
be bias in self-ratings of empathy by schizophrenia [55],
further studies should address this limitation in the future.
Last but not least, the classic chlorpromazine (CPZ) equiv-
alents that can be used to chart relative antipsychotic po-
tencies of antipsychotic drugs were not recorded in the
present study. Since it might be a factor in symptomology
in schizophrenia, future studies should also include CPZ
equivalents as a covariate.
Conclusions
By examining a broader concept of social cognition and
symptomatology and by separating neurocognition into
various factors, we could identify specific social and neuro-
cognitive impairment in schizophrenia. More importantly,
the findings suggest that neurocognitive impairment pre-
disposes people with schizophrenia to deficits in theory of
mind, which in turn increases symptomatology, including
negative and positive symptoms in schizophrenia. In other
words, we could better enhance clinical outcomes by im-
proving ToM ability in therapeutic treatment pertaining to
people with schizophrenia. For instance, an integrated
therapeutic approach with the combination of neurocogni-
tion and social cognition [56,57] might be a more effective
approach to treating the symptomatology of people with
schizophrenia.
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